Navigation Links
Optimer Pharmaceuticals and Clinical Investigators to Present Data at Upcoming Medical Meetings
Date:4/28/2011

SAN DIEGO, April 28, 2011 /PRNewswire/ -- Optimer Pharmaceuticals, Inc. (NASDAQ: OPTR) announced that additional data from the DIFICID™ Phase 3 trials will be presented at the following medical meetings:Digestive Disease Week (DDW), McCormick Place, Chicago, ILMay 7-10, 2011Poster Presentation Information:Title:

Risk of Recurrence and Time to Recurrence Following Treatment of Clostridium difficile Infection: Patient Characteristics and the Differential Effect of Fidaxomicin vs. VancomycinPresenter:

Kathleen M. Mullane, D.O.Date:

Saturday, May 7, 2011 Time:

12:00 p.m. to 2:00 p.m. Central TimeLocation:

Poster Session Hall A (MCP)Session:

Intestinal Disorders: Prebiotics, Probiotics and PathogensProgram #:

Sa1981Poster Presentation Information:Title:

High Fecal and Low Plasma Levels of Fidaxomicin and Metabolite OP-1118 inPatients with C. difficile infection:  Combined Results of Two Phase 3 TrialsPresenter:

Pamela S. Sears, Ph.D. Date:

Monday, May 9, 2011 Time:

12:00 p.m. to 2:00 p.m. Central TimeLocation:

Poster Session Hall A (MCP)Session:

Randomized Controlled Clinical TrialsProgram #:

Mo1160European Congress of Clinical Microbiology and Infectious Diseases and International Congress of Chemotherapy, Milano Convention Center, Milan, ItalyMay 7-10, 2011 Oral Presentation Information:Title:

Immunosuppression and the Risk of Death, Cure Rates and Disease RecurrenceAmong Patients with Clostridium difficile InfectionPresenter:

Yoav Golan, M.D., M.S.Date:

Tuesday, May 10, 2011 Time:

10:36 a.m. to 10:48 a.m. Central European TimeLocation:

Lecture Hall Brown 1Oral Session:

C. difficile NewsPresentation #:

O504Poster Presentation Information:Title:

Clostridium difficile Recurrence, Alcohol Consumption, and the Effect of Fidaxomicin vs. VancomycinPresenter:

Yoav Golan, M.D., M.S.Date:

Tuesday, May 10, 2011Time:

12:30 p.m. to 1:30 p.m. Central European TimeLocation:

Poster Area Hall 5Poster Topic 99:

Clostridium difficilePoster ID#:

P19682011 Annual Scientific Meeting of the American Geriatrics Society (AGS), The Gaylord National Hotel, National Harbor, MarylandMay 11-14, 2011Poster Presentation Information: Title:

Effect of Advancing Age on Outcomes of Therapy for Clostridium difficile InfectionPresenter:

Thomas J. Louie, M.D.Date:

Thursday, May 12, 2011 Time:

4:30 p.m. to 6:00 p.m. Eastern TimeSession:

Presidential Poster Session BLocation:

Exhibit HallPoster ID#:

B126About Optimer PharmaceuticalsOptimer Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing innovative hospital specialty products that have a positive impact on society. Optimer has two anti-infective product candidates in development, DIFICID™ (fidaxomicin) and Pruvel™ (prulifloxacin). DIFICID is a narrow spectrum antibiotic being developed for the treatment of Clostridium difficile infection (CDI). The FDA granted the Company's request for six-month Priority Review of Optimer's NDA for DIFICID, and has assigned a Prescription Drug User Fee Act (PDUFA) goal date of May 30, 2011. The Company also filed a MAA with the European Medicines Agency (EMA) for DIFICID. Pruvel™ is a prodrug in the fluoroquinolone class of antibiotics being developed as a treatment for infectious diarrhea. Additional information can be found at http://www.optimerpharma.com.  

ContactsOptimer Pharmaceuticals, Inc.
Christina Donaghy, Corporate Communications Manager
John D. Prunty, Chief Financial Officer & VP Finance
858-909-0736

Canale Communications
Jason I. Spark, Senior Vice President
619-849-6005


'/>"/>

SOURCE Optimer Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Optimer Pharmaceuticals Reports First Quarter 2009 Financial Results
2. Optimer Pharmaceuticals Announces Lower Recurrence Rates for Fidaxomicin Versus Vancocin(R) in Subgroup Analyses from Its Phase 3 Study for the Treatment of CDI
3. Optimer Pharmaceuticals to Present at June 2009 Investor Conferences
4. Optimer Pharmaceuticals to Present at the Canaccord Adams 29th Annual Global Growth Conference
5. Optimer Pharmaceuticals Reports Second Quarter 2009 Financial Results
6. Optimer Pharmaceuticals Announces Presentations of Additional Phase 3 Fidaxomicin and Prulifloxacin Data at Upcoming ICAAC Annual Meeting
7. Optimer Pharmaceuticals to Present at September 2009 Investor Conferences
8. Optimer Pharmaceuticals Reports Third Quarter 2009 Financial Results
9. Optimer Pharmaceuticals Phase 3 Clinical Trials show Fidaxomicin is Superior to Vancomycin in Treatment of Recurrent Clostridium difficile Infection (CDI); Data Presented at ICAAC
10. Optimer Announces Presentation of Additional Data from Fidaxomicin Phase 3 Study for the Treatment of Clostridium difficile Infection (CDI) Presented at ICAAC
11. Optimer Pharmaceuticals Announces Presentations at Upcoming IDSA Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... , December 8, 2016 ... für Molekulargenetik, erweitert seine Palette an anpassbaren SureSeq™ ... Custom FH Panels, das ein schnelles und kostengünstiges ... Das Panel bietet eine Erkennung von Einzel-Nukleotid-Variationen (Single ... mit einem einzigen kleinen Panel und ermöglicht eine ...
(Date:12/8/2016)... ... December 08, 2016 , ... Microbial genomics leader, uBiome, joins ... one of just six company finalists in the Health & Medicine category. Over ... nominated as finalists in this year’s awards include Google, SpaceX, Oculus, and SolarCity. ...
(Date:12/8/2016)... Dec. 8, 2016 Savannah River Remediation ... and selected NewTechBio,s NT-MAX Lake & Pond ... beneficial bacteria, in conjunction with Hexa Armor/ Rhombo ... with National Pollutant Discharge Elimination System requirements. ... a steady history of elevated pH levels, above ...
(Date:12/7/2016)... ... 07, 2016 , ... A new study published in the ... treated, advanced pancreatic cancer, liquid biopsies are not yet an adequate substitute for ... blood sampling may improve the value of a blood-based test.” The study was ...
Breaking Biology Technology:
(Date:11/29/2016)... CANNES, France , November 29, 2016 Nearly ... Continue Reading ... ... System is part of an efficient Identity Management. (PRNewsFoto/DERMALOG Identification Systems) ... DERMALOG is Germany's largest Multi-Biometric ...
(Date:11/21/2016)...   Neurotechnology , a provider of high-precision ... that the MegaMatcher On Card fingerprint matching algorithm ... NIST Minutiae Interoperability Exchange (MINEX) III ... of the evaluation protocol. The ... fingerprint templates used to establish compliance of template ...
(Date:11/15/2016)... Md. , Nov. 15, 2016  Synthetic ... company developing therapeutics focused on the gut microbiome, ... offering of 25,000,000 shares of its common stock ... common stock at a price to the public ... proceeds to Synthetic Biologics from the offering, excluding ...
Breaking Biology News(10 mins):